Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024)

Protalix BioTherapeutics has reported Short term Debt for 7 years, with the latest figure at $20.4 million in Q2 2024.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $20.4 million in Q2 2024; TTM through Jun 2024 was $20.4 million, a N/A change from a year earlier, with the FY2023 full-year figure at $20.3 million, changed N/A from the prior year.
• Short term Debt was $20.4 million for Q2 2024 at Protalix BioTherapeutics, roughly flat from $20.4 million in the prior quarter.
• The five-year high for Short term Debt was $56.4 million in Q2 2021, with the low at $3.2 million in Q3 2021.
• Average Short term Debt over 4 years is $31.3 million, with a median of $20.4 million recorded in 2024.